Cell & Gene by Oxford Global’s Post

Reflecting on a successful first day at the 42nd JPM Healthcare Conference with GenScript, GenScript ProBio, and Legend Biotech!   Ying Huang, CEO of Legend Biotech, shared the positive strides and future outlook of Legend Biotech's cell therapy research and development pipeline.   Looking ahead to day two, Li Chen, CEO of GenScript Probio, will present on January 10, exploring Probio's strengths in drug discovery and the CDMO field.   We will also host the GenScript Biotech Global Forum 2024, bringing together leaders from academia, regulatory agencies, enterprises, and the capital market to explore the future development of these therapies and build a platform for mutual exchange and cooperation.   Stay tuned for updates as we navigate the forefront of biotech innovation at the JPM Healthcare Conference!   Find more details here: https://lnkd.in/eVuenHDT #biotechnology #lifesciences #genetherapy #celltherapy #biotechindustry #GSforum2024

Washington University launches translational DiviTum® TKa trial: BettER! This study seeks to evaluate the impact of early therapeutic switching based on biomarker-driven insights, utilizing DiviTum TKa to guide treatment decisions. Read the full Press release: https://loom.ly/ay43Vvg "We are thrilled to once again collaborate with Washington University on another trial. This time it is a translational trial, which if successful would pave the way for increased uptake of DiviTum TKa, for the benefit of patients," said Anders Rylander, CEO of Biovica. #PrecisionMedicine #clinicaltrials #biomarkers #bcsm #investors #biovicb

Slides from the recent keynote "Biopharma Dealmaking: Time for a Re-Think" I delivered at the Swiss Healthcare Licensing Group meeting in Montreux in May are now available on the Lumanity website. https://lnkd.in/ePi9Vwse This data rich presentation is important viewing for anyone involved with or interested in biotech corp dev strategy but especially for those pre-commercial biotech "sellers" pinning their hopes on a large pharma partnership. The historically unprecedented increase in the number of biotechs reaching or surpassing clinical PoC stage (5 x or greater over past decade) coupled with a limited number of large pharma "buyers" means odds for vast majority of would be sellers are long. Many more of these biotechs should start to see self-commercializing, especially those pursuing advanced therapeutic modalities, such as cell and gene therapy, as more of a "Plan A" than B. And for many of these companies the time to get started is now, not when they are late in P3 or beyond.

Fascinating analysis from Ed Saltzman. In the current environment, it is time for #biotechs to rethink exit strategies and prioritize current resources to derisk commercial #risks, especially for novel/complex modalities. Novel technology platforms should also focus on demonstrating agile #CMC production process to increase incentives for partnering. However, self-commercialization should also be on the table regarding next steps. #drugdevelopment #biotech #investor #partnering #businessdevelopment #riskassessment

The last ImmunoWatch for 2023 is focused on Therapeutic Cytokines, download it to learn more on this innovative field of biotherapies :) And if you look closely enough you'll find the topics for our 2024 Watches! #mabdesign #therapeuticcytokines #biotherapies #mabdesignwatchs

📅 Save the Date: September 7th! Join us for the second in a series of Oncofactory’s webinars showcasing new ERBC's innovative technology platform for the evaluation of novel anticancer agents. Our platform is based on an #avian embryo patient-derived xenograft (AVI-PDX) model developed and patented by Oncofactory, an ERBC Group company. This interactive webinar will answer your burning questions about the real-world application of the AVI-PDX model. With Valerie Castellani Lincontang, PhD, Founder and Chief Scientific Officer of Oncofactory, and guest speaker Karine Aguera, Chief Development Officer at StromaCare, previously R&D Project leader at ERYTECH Pharma. 👉 Register here: https://lnkd.in/e9rJWMFA Not available? Register anyway and get access to the session replay. Also, mark your calendars for our third webinar on September 28, 2023, where we will delve into clinical case studies. (Link to register: https://lnkd.in/eWn5hBEF) See you soon. For more information on the Oncofactory platform overview and to view the Webinar 1 replay, click here: https://lnkd.in/eYhXF2Ns #Lifescience #testing #efficacy #research #PDXmodel #invivomodels #CRO #drugdevelopment #ethicalpractice #NAM #nonclinical #biotech #TNBC

We are delighted to be showcased as one of the 50 companies in PwC UK’s 'Life Sciences Future 50' report, illustrating the world-class science and innovation being led by the UK’s life sciences sector to solve some of the most important challenges in scientific research and human healthcare. At Sitryx we are focused on advancing our broad pipeline of potential therapeutics that intervene in cell metabolism, opening new avenues for the treatment of chronic autoimmune and inflammatory diseases and driving better patient outcomes. To learn more about what Sitryx and other promising companies are up to read the full report 👉 https://bit.ly/3Fnw379   #LifeSciences #BioTech #CellMetabolism #drugDiscovery #drugDevelopment #immunometabolism #autoimmune #biopharma #biotechnology #PwCFuture50

Using #Microbiome insights in drug discovery - this is one of the mission of Oncodesign Services! Discover below, how studying Microbiome could help the development of innnovative therapies 👇👇 For more information on our Microbiome platform ➡️ https://ow.ly/N6Zq50OVIhY #microbiome #microbiota #drugdiscovery #newtherapies

📑 Work Packages. #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain. Are you curious about AVITHRAPID's WP2 ( INSTITUT NATIONAL DE RECHERCHE EN SCIENCES ET TECHNOLOGIES POUR L'ENVIRONNEMENT ET L'AGRICULTURE – France)? Take a look below! 🔎 👇

#AntibodyDrugConjugates (ADCs) differ from #radiopharmaceuticals regarding one important mechanistic aspect: They need to be internalized by the target cell to have the toxic payload take effect. How can #DARPinDrugConjugates (DDCs) help in that space?   Effective treatment with drug conjugates requires that the toxin is released inside of the cells.   The first step in this mechanism is the clustering of receptors on the cell surface that triggers the formation of endosomes, which will include any receptor-bound drug conjugates. Inside the cells, the endosomes may then fuse with lysosomes and become degraded, thus releasing the toxin, or simply recycle back to the cell surface without releasing the toxin.   Think of it as a revolving door: To get beyond it, you must not stay for a full round but exit on the opposite side of it. Similarly, an effective #DrugConjugate should not ride a full round of receptor recycling, but ideally exit the carousel inside the cell.   Clustering the targeted receptor molecules with #mAbs or #DARPins – the binding moieties of ADCs or DDCs - can facilitate this process. One publication that nicely illustrates this effect for DARPins is a study on EGFR-binding DARPins by Ykelien L. Boersma et al. (https://lnkd.in/efKfHFZB): By combining DARPin domains recognizing two different epitopes on #EGFR, a bispecific, tetravalent DARPin was created that significantly inhibits receptor recycling, so that more EGFR ended up in lysosomes and stayed inside the cells. Finding the perfect DrugConjugate that replicates such effect will always be a matter of testing different epitopes, affinities, valencies and binding geometries.   The plug & play versatility of the #DARPin technology helps to make that discovery process more efficient, thus holding great promise for the future development of DDCs.     #Athebio  #drugdevelopment